Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCO-010 in Retinitis Pigmentosa
NCT04945772Phase 2Completed
- Sponsor
- Nanoscope Therapeutics
- Start
- Jul 2021
- Primary completion
- Feb 2023
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
A Phase 2 trial of sonpiretigene isteparvovec in retinitis pigmentosa (RP), sponsored by Nanoscope Therapeutics. Started Jul 2021; status: completed.
02
Drugs
sonpiretigene isteparvovec
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT04945772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04945772.